What is the difference between Cartalax and Rigin?

Cartalax: Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells Rigin: Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

Is Cartalax FDA approved?

Cartalax is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Rigin FDA approved?

Rigin is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cartalax administered in research settings?

In research settings, Cartalax is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Rigin administered in research settings?

In research settings, Rigin is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cartalax vs Rigin

Peptide Comparison

Cartalax vs Rigin

Name: Cartalax vs Rigin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Skin & Cosmetic peptides.

Cartalax

Ala-Glu-Asp-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

6 providers listed

Full Cartalax profile →

Rigin

Palmitoyl Tetrapeptide-7

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

2 providers listed

Full Rigin profile →

Bottom line

Cartalax has published research citations on file; Rigin does not yet — the main evidence gap between them.

Quick Verdict

Cartalax

Evidence

Preclinical

Rigin

Evidence

Not rated

Which One Should You Choose?

Your goal	Better option
Has published research citations	Cartalax
Oral administration option	Cartalax
More provider options (6 vs 2)	Cartalax

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cartalax

Rigin

Mechanism Family

Skin & Cosmetic

Half-life

Unknown

N/A (topical)

FDA Status

not evaluated

Admin Routes

subcutaneous, oral

topical

Availability

Research Only

Providers

6 listed

2 listed

Avail. Notes

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Cosmetic peptide (palmitoyl tetrapeptide-7). Anti-inflammatory cosmetic ingredient. Not regulated as a drug by FDA. No NDA or IND. Cosmetic use only in skincare formulations.

Research Evidence

Cartalax

PreclinicalIn vitro · 1 key study · most recent 2023

Rigin

No citations on file

Research Citations

Cartalax

In vitro2023 · Advances in Gerontology

KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cell…

Rigin

No citations on file.

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Research Areas

cartilage regenerationjoint repairchondrocyte function support

About Rigin

Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

Research Areas

anti-inflammatory (skin)skin tighteningextracellular matrix supportwrinkle reduction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cartalax

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Rigin

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Cartalax

$2.75/mg

$2.06 – $3.00 range

12 vendors

View price index →Find providers →

Rigin

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cartalax

6 listed

Browse directory →

Providers offering

Rigin

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cartalax vs Rigin — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cartalax/rigin

https://peptidebase.io/peptides/compare/cartalax/rigin Methodology License Download JSON Download CSV